Beyond VEGF—The Weisenfeld lecture

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 15, 2016, Pages 6911-6918

  Miller, Joan W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ATORVASTATIN; BEVACIZUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGAPTANIB; RANIBIZUMAB; SIMVASTATIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANTIANGIOGENIC THERAPY; ARTICLE; ATROPHY; CELL ADHESION; CELL STRESS; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; HYPERPIGMENTATION; IMMUNITY; INFLAMMATION; LASER COAGULATION; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINAL PIGMENT EPITHELIUM; SUBRETINAL NEOVASCULARIZATION; TOXICITY; VISUAL ACUITY; ANIMAL; ANTAGONISTS AND INHIBITORS; MACULAR DEGENERATION; METABOLISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MACULAR DEGENERATION; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85008180721     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-21201     Document Type: Article

References (44)

1. Priority Eye Diseases. World Health Organization website. Available at: http://www.who.int/blindness/causes/priority. Accessed July 1, 2015.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
3. Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med. 2006;355:1432–1444.
4. Martin DF, Maguire MG, Ying GS, et al.; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
5. Martin DF, Maguire MG, Fine SL, et al.; CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398.
6. Chakravarthy U, Harding SP, Rogers CA, et al.; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119:1399–1411.
7. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013;120:2300–2309.
8. Krebs I, Schmetterer L, Boltz A, et al. A randomised doublemasked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97: 266–271.
9. Schauwvlieghe AM, Dijkman G, Hooymans JM, et al. Ranibizumab versus bevacizumab in the Netherlands: comparing the efficacy of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration – the BRAMD Study. Ophthalmologica. 2013;230(suppl 1):2–3.
10. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122:146–152.
11. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.e55.
12. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVENUP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299.
13. Peden MC, Suner IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of antivascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122:803–808.
14. Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915–924.
15. Green WR. Histopathology of age-related macular degeneration. Mol Vis. 1999;5:27.
16. Grunwald JE, Pistilli M, Ying GS, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122:809–816.
17. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002;43:1986–1993.
18. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on M¨uller cells and photoreceptors. PLoS One. 2008;3: e3554.
19. Hisatomi T, Sakamoto T, Murata T, et al. Relocalization of apoptosis-inducing factor in photoreceptor apoptosis induced by retinal detachment in vivo. Am J Pathol. 2001;158:1271–1278.
20. Matsumoto H, Miller JW, Vavvas DG. Retinal detachment model in rodents by subretinal injection of sodium hyaluronate. J Vis Exp. 2013;79:50660.
21. Murakami Y, Notomi S, Hisatomi T, et al. Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog Retin Eye Res. 2013;37:114–140.
22. Zacks DN, Hanninen V, Pantcheva M, Ezra E, Grosskreutz C, Miller JW. Caspase activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2003;44:1262–1267.
23. Zacks DN, Zheng QD, Han Y, Bakhru R, Miller JW. FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2004;45:4563–4569.
24. Nakazawa T, Kayama M, Ryu M, et al. Tumor necrosis factoralpha mediates photoreceptor death in a rodent model of retinal detachment. Invest Ophthalmol Vis Sci. 2011;52:1384–1391.
25. Schweichel JU, Merker HJ. The morphology of various types of cell death in prenatal tissues. Teratology. 1973;7:253–266.
26. Chan FK, Shisler J, Bixby JG, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem. 2003;278:51613–51621.
27. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–119.
28. Trichonas G, Murakami Y, Thanos A, et al. Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc Natl Acad Sci U S A. 2010;107:21695–21700.
29. Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med. 2008;359:1456–1463.
30. Murakami Y, Matsumoto H, Roh M, et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMPmediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ. 2014;21:270–277.
31. Kataoka K, Matsumoto H, Kaneko H, et al. Macrophage- and RIP3-dependent inflammasome activation exacerbates retinal detachment-induced photoreceptor cell death. Cell Death Dis. 2015;6:e1731.
32. Matsumoto H, Murakami Y, Kataoka K, et al. Membrane-bound and soluble Fas ligands have opposite functions in photoreceptor cell death following separation from the retinal pigment epithelium. Cell Death Dis. 2015;6:e1986.
33. Miller JW. Age-related macular degeneration revisited–piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013;155:1–35.e13.
34. Curcio CA, Johnson M, Rudolf M, Huang JD. The oil spill in ageing Bruch membrane. Br J Ophthalmol. 2011;95:1638–1645.
35. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database Syst Rev. 2015;2: CD006927.
36. Guymer RH, Baird PN, Varsamidis M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. PLoS One. 2013;8:e83759.
37. VanderBeek BL, Zacks DN, Talwar N, Nan B, Stein JD. Role of statins in the development and progression of age-related macular degeneration. Retina. 2013;33:414–422.
38. Cougnard-Gregoire A, Delyfer MN, Korobelnik JF, et al. Elevated high-density lipoprotein cholesterol and age-related macular degeneration: the Alienor study. PLoS One. 2014;9: e90973.
39. Klein R, Myers CE, Buitendijk GH, et al. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. Am J Ophthalmol. 2014;158:513–524.
40. Rogers SL, Magliano DJ, Levison DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther. 2007;29: 242–252.
41. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70–76.
42. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38.
43. Zhao XQ, Dong L, Hatsukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging. 2011;4:977–986.
44. Vavvas DG, Daniels AB, Kapsala ZG, et al. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. EBioMedicine. 2016;5:198–203